A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.

Guardado en:
Detalles Bibliográficos
Autores principales: Michael A. Crone, Miles Priestman, Marta Ciechonska, Kirsten Jensen, David J. Sharp, Arthi Anand, Paul Randell, Marko Storch, Paul S. Freemont
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares